SCHEMBL2592673

SCHEMBL2592673

O=CNc1nc(-c2ccc([N+](=O)[O-])o2)cs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.46
▸ NPC1 O15118 5/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 7/20 0.45
▸ RAB9A P51151 6/20 0.45
▸ MCL1 Q07820 3/20 0.45
▸ POLB P06746 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MITF O75030 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ SLC2A1 P11166 1/20 0.43
▸ EGFR P00533 1/20 0.41
▸ CHEK1 O14757 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ PAK4 O96013 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nifurthiazole SCHEMBL194337 0.87 HSP90AA1 (0.45) HSP90AA1NPC1MEN1KMT2AMAPT
SCHEMBL29376467 0.80 NPC1 (0.47) HSP90AA1NPC1MEN1KMT2AMAPT
SCHEMBL3824030 0.79 RAB9A (0.62) HSP90AA1NPC1MEN1KMT2AMAPT
SCHEMBL18588878 0.77 MAPT (0.53) HSP90AA1NPC1MEN1KMT2AMAPT
SCHEMBL3344653 0.77 MAPT (0.53) HSP90AA1NPC1MEN1KMT2AMAPT
SCHEMBL29500370 0.70 MAPT (0.57) NPC1MEN1KMT2AMAPTRAB9A
SCHEMBL11827105 0.69 NPC1 (0.49) HSP90AA1NPC1MEN1KMT2AMAPT
SCHEMBL11827112 0.69 NPC1 (0.49) HSP90AA1NPC1MEN1KMT2AMAPT
SCHEMBL4503044 0.67 MEN1 (0.60) NPC1MEN1KMT2AMAPTRAB9A
SCHEMBL5901944 0.66 SLC2A1 (0.42) HSP90AA1NPC1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257125-A1 HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF SCHOLAR ROCK INC (US) 2025-08-14 — — US disclosed
US-20250215072-A1 ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF SCHOLAR ROCK, INC. 2025-07-03 — — US disclosed
WO-2025078478-A1 CANDIDA AFRICANA FOR USE IN THE TREATMENT OF CANCER AB MAURI (UK) LTD (GB) 2025-04-17 — — WO disclosed
US-12252531-B2 Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors SCHOLAR ROCK, INC. (US) 2025-03-18 — — US disclosed
US-12122823-B2 Isoform-selective TGFB1 inhibitors and use thereof SCHOLAR ROCK, INC. (US) 2024-10-22 — — US disclosed
US-20230092707-A1 METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY MERCK SHARP & DOHME LLC (US) 2023-03-23 — — US disclosed
US-20230057012-A1 TGFB INHIBITORS AND USE THEREOF SCHOLAR ROCK, INC. 2023-02-23 — — US disclosed
US-20230050148-A1 TGF-BETA INHIBITORS AND USE THEREOF SCHOLAR ROCK, INC. 2023-02-16 — — US disclosed
EP-4114863-A1 METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY Merck Sharp & Dohme LLC (US) 2023-01-11 — — EP disclosed
EP-4087659-A2 TGF-BETA INHIBITORS AND USE THEREOF Scholar Rock, Inc. (US) 2022-11-16 — — EP disclosed
US-4877872-A DETECTING AND TREATING TUMORS THE UNIVERSITY OF TOLEDO (US) 1989-10-31 — — US disclosed
EP-0256036-A1 PRODUCTION AND USE OF PURPURINS, CHLORINS AND PURPURIN- AND CHLORIN-CONTAINING COMPOSITIONS. UNIV TOLEDO (US) 1988-02-24 — — EP disclosed
WO-1987004071-A1 PRODUCTION AND USE OF PURPURINS, CHLORINS AND PURPURIN- AND CHLORIN-CONTAINING COMPOSITIONS THE UNIVERSITY OF TOLEDO (US) 1987-07-16 — — WO disclosed
US-4640912-A IRRIGATION SURFACES WITH AQUEOUS SOLUTION BIOMED RESEARCH, INC. 1987-02-03 — — US disclosed
EP-0027133-B1 AN IN VITRO METHOD FOR DETERMINING MALIGNANCY IN MAMMALIAN TISSUE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1985-02-20 — — EP disclosed
US-4334017-A Method for detecting cancer in mammalian tissue MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1982-06-08 — — US disclosed
EP-0027133-A4 AN IN VITRO METHOD FOR DETERMINING MALIGNANCY IN MAMMALIAN TISSUE. MASSACHUSETTS INST TECHNOLOGY (US) 1981-08-27 — — EP disclosed
EP-0027133-A1 AN IN VITRO METHOD FOR DETERMINING MALIGNANCY IN MAMMALIAN TISSUE. MASSACHUSETTS INST TECHNOLOGY (US) 1981-04-22 — — EP disclosed
WO-1980002296-A1 ENZYMATIC METHOD FOR DETECTING CANCER IN MAMMALIAN TISSUE MASSACHUSETTS INST TECHNOLOGY (US) 1980-10-30 — — WO disclosed
US-4132600-A MEASURING LEVEL OF GALACTOSYL TRANSFERASE ACTIVITY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1979-01-02 — — US disclosed
Send feedback